Lergiset-AF Nasal Spray is a combination pharmaceutical formulation containing Fluticasone Propionate (50 mcg) and Azelastine Hydrochloride (140 mcg) per actuation, designed for the management of allergic rhinitis symptoms. Fluticasone Propionate is a potent synthetic corticosteroid with anti-inflammatory properties that effectively reduces nasal mucosal inflammation, edema, and congestion. Azelastine is a selective second-generation antihistamine that provides rapid relief by blocking histamine H1 receptors, thereby alleviating symptoms such as sneezing, nasal itching, and rhinorrhea. The dual-action mechanism of Lergiset-AF offers both immediate symptomatic relief and long-term control of nasal allergy symptoms. This nasal spray is indicated for the treatment of seasonal and perennial allergic rhinitis in adults and adolescents aged 12 years and above. It is administered intranasally, typically two sprays in each nostril twice daily, ensuring targeted delivery with minimal systemic absorption. Lergiset-AF Nasal Spray is generally well-tolerated; however, patients may experience mild adverse effects such as nasal irritation, dryness, or a bitter taste. It is contraindicated in patients with hypersensitivity to any of its components. Use during pregnancy and lactation should be under medical supervision. Lergiset-AF Nasal Spray provides an effective therapeutic option for comprehensive allergic rhinitis management.